A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue
Latest Information Update: 12 Feb 2026
At a glance
- Drugs Dengue tetravalent vaccine Takeda (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Takeda
Most Recent Events
- 09 Feb 2026 Status changed from not yet recruiting to recruiting.
- 04 Apr 2025 Planned End Date changed from 14 Mar 2026 to 14 Apr 2027.
- 04 Apr 2025 Planned primary completion date changed from 14 Mar 2026 to 14 Apr 2027.